bpc 157 multiple sclerosis clinical trial humans Frontiers Stable gastric pentadecapeptide BPC 157
Description
Pivotal Phase 3 trials Trial SURMOUNT-1 (NEJM 2022) Population 2,539 adults, obesity, no diabetes
Communications 15, 8604
BPC 157 therapy counteracted both the MDA-value increase as well as the oxidative stress damages in all organs tested at the end of all decompression/reperfusion periods, which were investigated to provide additional proof for the concept (Table 4)
[DOI] [PMC free article] [PubMed] [Google Scholar] 81.Cant C et al
MK-677 supports muscle preservation, bone density, and better sleep quality
Tell us your symptoms, how you treated it, and how long it took to stop the symptoms
